Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Convatec False /oidc-signin/en-us/

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

Convatec announces the introduction of ConvaFoam™

New wound care solution simplifies choice for healthcare professionals, patients and caregivers

(Bridgewater, New Jersey, January 3, 2023) – Convatec is pleased to announce the US launch of ConvaFoam™, a family of advanced foam dressings designed to address the needs of healthcare providers and their patients. ConvaFoam™ can be used on a spectrum of wound types at any stage of the wound journey, making it the simple dressing choice for wound management and skin protection.

Hard-to-heal wounds are a silent epidemic with substantial economic, clinical, and social burden that is set to continue rising1. Multiple factors can make wound treatment challenging, but at Convatec, we believe there is always a road to recovery.

ConvaFoam™ has been specifically designed to help address the silent epidemic​ by removing the complexity of wound care and offering healthcare providers and patients more than just a dressing.

“Through active listening, combined with our heritage of advancing wound care technologies, we have created a high-performance product range that makes the choice of dressings simpler for healthcare professionals, caregivers and patients,” said David Shepherd, President and Chief Operating Officer, Advanced Wound Care at Convatec.

The ConvaFoam™ family of dressings includes enhanced silicone technology for improved adhesion2; improved absorbency fluid handling; 7 day wear time3; a patterned film design that may help to aid exudate monitoring3; and a superabsorbent layer. ConvaFoam can also be cut to size, aiding application to difficult-to-dress areas.

ConvaFoam™ is more than a dressing – it’s a wound care service providing extra educational support where needed. Market research conducted amongst wound care patients in the United States, Germany4, indicated that 72% of patients change their dressing themselves, while 23% have help from a formal caregiver or by their family. But 44% of patients state that they struggle with being compliant with their wound care treatment plan. To support and guide patients, caregivers and healthcare professionals throughout dressing changes, Convatec have added QR codes on each ConvaFoam™ packaging, leading to a host of educational videos.

Consistent with our promise to be ‘forever caring’, Convatec has been committed to pioneering advanced wound care solutions for more than 40 years. We believe that every wound should have the best chance to heal. By putting the needs of patients and the people who care for them at the center of our research and development, we strive to make wound care more effective and manageable. As well as advancing wound care products, we share our expertise through offering tailored customer support, and developing value-added tools and guides, all with the aim to improve patient outcomes and reduce the overall cost of care.

For more information about ConvaFoam™, please visit www.convatec.com.

Convatec Group Plc  

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. With around 10,000 colleagues, and a promise to be forever caring, our products and services are available in over 100 countries. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. The company is a constituent of the FTSE 100 Index (LSE:CTEC) and in 2021 revenues were over $2 billion. To learn more about Convatec, please visit http://www.convatecgroup.com  

  1. Sen CK. Human Wound and Its Burden: Updated 2020 Compendium of Estimates. Adv Wound Care (New Rochelle). 2021 May;10(5):281-292.​

  2. WHRI8050 MS172 Adhesion Characteristics of ConvaFoam™.

  3. WHRI8051 MS173 In-vitro Performance Characteristics of ConvaFoam™.

  4. Sector & Segment Market Research, September 2021.

Press Release

See all

1/3/2023

Convatec announces the introduction of ConvaFoam™

ConvaFoam release

Convatec announces the introduction of ConvaFoam™

Read more

11/17/2022

Capital Markets Event

Read more

11/10/2022

Trading Update for the 10 months ended 31 October 2022

Read more

8/4/2022

Interim Results for the six months ended 30 June 2022

Read more

5/12/2022

Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences Inc

Read more

2/28/2022

Non-Executive Directors - Appointment and Resignation

Read more

3/8/2022

Annual Results for the twelve months ended 31 December 2021

Read more

3/14/2022

Convatec Group completes acquisition of Triad Life Sciences Inc as it enters attractive wound biologics segment

Read more

5/13/2022

Convatec invests in BlueWind Medical to fund development of innovative neuromodulation technology

Read more

5/12/2022

AGM trading update for the four months ended 30 April 2022

Read more

1/27/2022

Board committee changes

Read more

5/18/2022

Convatec makes 'forever caring' promise to patients and healthcare providers

Read more